SURVYR

LGND

Ligand Pharmaceuticals Incorporated
$318.78
+$7.05 (2.26%)Oct 28 close
Health CareS&P 600 CompareTechnicals
1M3M6M1Y2Y
-7%+12%+32%+52%+72%Oct 2025Oct 2026Apr 202652w high $326.6352w low $175.89
LGNDSPY
Wall St. Highest PT $406.00 (+27.4%) Wall St. Avg PT $345.75 (+8.5%)
$182$241$300$359$418POC $207Hi $406Avg $346
Underwater Drawdown %Max DD -14.7%Current -1.2%
0.0%-14.7%
Relative Strength vs SPY+53.9% vs SPYOutperforming
+68%0%-68%
1W
+$11.04 (3.59%)
1M
+$4.68 (1.49%)
3M
+$30.77 (10.68%)
6M
+$93.92 (41.77%)
YTD
+$129.71 (68.60%)
1Y
+$129.91 (68.78%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
12 analysts · mean score 1.27
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$318.78
Average target$345.75
+$26.97 (+8.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$247.00
Median$345.75
High$406.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-09-25 · Barclays started covering LGND at Overweight
Reiterated
2026-09-24 · HC Wainwright & Co. reiterated Buy on LGND
Reiterated
2026-09-23 · Citigroup reiterated Buy on LGND
Initiated
2026-08-14 · Leerink Partners started covering LGND at Outperform
Reiterated
2026-08-07 · RBC Capital reiterated Outperform on LGND
Reiterated
2026-08-06 · HC Wainwright & Co. reiterated Buy on LGND
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$6.1B
P/E (last 12 months)32.4
P/E (next 12 months, estimated)25.7
52-week range$175.89 – $326.63
Revenue growth (latest quarter vs a year ago)+33.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (12)
Average analyst price target$345.75 (+8%)

What they do

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma. The company also provides Teriparatide injection product for osteoporosis.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
82nd percentile in sector
A-
12-1 return: +63.3%
Percentile within its GICS sector across the S&P 1500.
Growth
91st percentile in sector
A
Revenue growth (YoY): +33.7%
Percentile within its GICS sector across the S&P 1500.
Value
17th percentile in sector
D
Forward E/P: 4.0% · EBITDA/EV: 2.3%
Percentile within its GICS sector across the S&P 1500.
Profitability
88th percentile in sector
A
Profit margin: +67.9% · Return on equity: +22.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
ranked 27 of 589 · 12-month momentum 64.1%
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

LGND earningsReports today
Next report · quarter Sep 2026
Thu Oct 29, 2026Before the open
EPS consensus$2.33 range $1.93–$2.49
Revenue consensus$77.2M 11 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026$2.37est $1.95+21.5%Above estimates
May 7, 2026$1.63est $1.80−9.6%Below estimates
Feb 26, 2026$2.02est $1.50+34.9%Above estimates
Nov 6, 2025$3.09est $1.93+60.5%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 11:28:55 ET
24-1125-0225-0525-0825-1126-0226-0526-080.003.09
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$63.7M+33.7%
2026-03-31$51.7M–
2025-12-31$59.7M–
2025-09-30$115.5M–
2025-06-30$47.6M–

Recent dividends

2007-04-03: $9.357

News & catalysts

More news
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
MT Newswires · Oct 19
BofA Securities Adjusts Price Target on Ligand Pharmaceuticals to $406 From $388, Maintains Buy Rating
MT Newswires · Oct 19
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
GlobeNewswire · Oct 15
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
Simply Wall St. · Sep 29
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
Simply Wall St. · Sep 29
Rating changes
Initiated
2026-09-25 · Barclays started covering LGND at Overweight
Reiterated
2026-09-24 · HC Wainwright & Co. reiterated Buy on LGND
Reiterated
2026-09-23 · Citigroup reiterated Buy on LGND
Initiated
2026-08-14 · Leerink Partners started covering LGND at Outperform
Reiterated
2026-08-07 · RBC Capital reiterated Outperform on LGND
Reiterated
2026-08-06 · HC Wainwright & Co. reiterated Buy on LGND

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$5.2K
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$72.2K
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$123.7K
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$467.4K
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$599.8K
Reardon Andrew
CLO & Secretary · 2026-10-02
Sell
$252.0K
Zimmermann Martine
Director · 2026-09-10
Sell
$342.0K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sell
$115.6K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sell
$110.7K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sell
$605.6K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sell
$513.3K
Reardon Andrew
CLO & Secretary · 2026-09-03
Sell
$85.2K

Stats refreshed 2026-10-21 11:28:55 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026